A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Ilginatinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors NS Pharma
- 04 Jun 2024 Status changed from recruiting to discontinued. (The study was stopped due to a business decision)
- 16 Apr 2024 Planned End Date changed from 24 Apr 2024 to 24 May 2024.
- 16 Apr 2024 Planned primary completion date changed from 24 Mar 2024 to 24 May 2024.